Literature DB >> 19375967

Mechanism of shortened bones in mucopolysaccharidosis VII.

Jason A Metcalf1, Yanming Zhang, Matthew J Hilton, Fanxin Long, Katherine P Ponder.   

Abstract

Mucopolysaccharidosis VII (MPS VII) is a lysosomal storage disease in which deficiency in beta-glucuronidase results in glycosaminoglycan (GAG) accumulation in and around cells, causing shortened long bones through mechanisms that remain largely unclear. We demonstrate here that MPS VII mice accumulate massive amounts of the GAG chondroitin-4-sulfate (C4S) in their growth plates, the cartilaginous region near the ends of long bones responsible for growth. MPS VII mice also have only 60% of the normal number of chondrocytes in the growth plate and 55% of normal chondrocyte proliferation at 3weeks of age. We hypothesized that this reduction in proliferation was due to C4S-mediated overactivation of fibroblast growth factor receptor 3 (FGFR3). However, MPS VII mice that were FGFR3-deficient still had shortened bones, suggesting that FGFR3 is not required for the bone defect. Further study revealed that MPS VII growth plates had reduced tyrosine phosphorylation of STAT3, a pro-proliferative transcription factor. This was accompanied by a decrease in expression of leukemia inhibitory factor (LIF) and other interleukin 6 family cytokines, and a reduction in phosphorylated tyrosine kinase 2 (TYK2), Janus kinase 1 (JAK1), and JAK2, known activators of STAT3 phosphorylation. Intriguingly, loss of function mutations in LIF and its receptor leads to shortened bones. This suggests that accumulation of C4S in the growth plate leads to reduced expression of LIF and reduced STAT3 tyrosine phosphorylation, which results in reduced chondrocyte proliferation and ultimately shortened bones.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19375967      PMCID: PMC2775472          DOI: 10.1016/j.ymgme.2009.03.005

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  55 in total

1.  Catalytically active TYK2 is essential for interferon-beta-mediated phosphorylation of STAT3 and interferon-alpha receptor-1 (IFNAR-1) but not for activation of phosphoinositol 3-kinase.

Authors:  M R Rani; D W Leaman; Y Han; S Leung; E Croze; E N Fish; A Wolfman; R M Ransohoff
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

2.  Constitutive expression of IL-6-LIKE cytokines in normal bone marrow: implications for pathophysiology of myeloma.

Authors:  B E Barton; T F Murphy
Journal:  Cytokine       Date:  2000-10       Impact factor: 3.861

3.  Induction of apoptosis and Fas receptor/Fas ligand expression by ischemia/reperfusion in cardiac myocytes requires serine 727 of the STAT-1 transcription factor but not tyrosine 701.

Authors:  A Stephanou; T M Scarabelli; B K Brar; Y Nakanishi; M Matsumura; R A Knight; D S Latchman
Journal:  J Biol Chem       Date:  2001-04-17       Impact factor: 5.157

4.  Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase.

Authors:  H H Li; W H Yu; N Rozengurt; H Z Zhao; K M Lyons; S Anagnostaras; M S Fanselow; K Suzuki; M T Vanier; E F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

5.  A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome).

Authors:  M Bhaumik; V J Muller; T Rozaklis; L Johnson; K Dobrenis; R Bhattacharyya; S Wurzelmann; P Finamore; J J Hopwood; S U Walkley; P Stanley
Journal:  Glycobiology       Date:  1999-12       Impact factor: 4.313

6.  Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB.

Authors:  Kazuhiro Ohmi; David S Greenberg; Kavitha S Rajavel; Sergey Ryazantsev; Hong Hua Li; Elizabeth F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

7.  Leukaemia inhibitory factor (lif) is expressed in hypertrophic chondrocytes and vascular sprouts during osteogenesis.

Authors:  E Grimaud; F Blanchard; C Charrier; F Gouin; F Redini; D Heymann
Journal:  Cytokine       Date:  2002-12-07       Impact factor: 3.861

8.  Expression of leukemia inhibitory factor (LIF)/interleukin-6 family cytokines and receptors during in vitro osteogenesis: differential regulation by dexamethasone and LIF.

Authors:  F Liu; J E Aubin; L Malaval
Journal:  Bone       Date:  2002-07       Impact factor: 4.398

9.  IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.

Authors:  Py Palmqvist; Emma Persson; H Herschel Conaway; Ulf H Lerner
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

10.  Genetic manipulation of hedgehog signaling in the endochondral skeleton reveals a direct role in the regulation of chondrocyte proliferation.

Authors:  F Long; X M Zhang; S Karp; Y Yang; A P McMahon
Journal:  Development       Date:  2001-12       Impact factor: 6.868

View more
  24 in total

1.  Potential role of cathepsin K in the pathophysiology of mucopolysaccharidoses.

Authors:  Susan Wilson; Dieter Brömme
Journal:  J Pediatr Rehabil Med       Date:  2010

2.  Chondroitin sulfate and growth factor signaling in the skeleton: Possible links to MPS VI.

Authors:  Tamara Alliston
Journal:  J Pediatr Rehabil Med       Date:  2010

3.  Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I.

Authors:  Raymond Y Wang; Afshin Aminian; Michael F McEntee; Shih-Hsin Kan; Calogera M Simonaro; William C Lamanna; Roger Lawrence; N Matthew Ellinwood; Catalina Guerra; Steven Q Le; Patricia I Dickson; Jeffrey D Esko
Journal:  Mol Genet Metab       Date:  2014-06-06       Impact factor: 4.797

4.  New Prospects for Restoring Skeletal Growth in Mucopolysaccharidoses.

Authors:  Eric A Espiner; Timothy C R Prickett
Journal:  Endocrinology       Date:  2020-04-01       Impact factor: 4.736

5.  The effect of Tlr4 and/or C3 deficiency and of neonatal gene therapy on skeletal disease in mucopolysaccharidosis VII mice.

Authors:  Elizabeth M Xing; Susan Wu; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2014-12-19       Impact factor: 4.797

6.  Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses.

Authors:  Calogera M Simonaro; Yi Ge; Efrat Eliyahu; Xingxuan He; Karl J Jepsen; Edward H Schuchman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

7.  Long circulating enzyme replacement therapy rescues bone pathology in mucopolysaccharidosis VII murine model.

Authors:  Daniel J Rowan; Shunji Tomatsu; Jeffrey H Grubb; Bisong Haupt; Adriana M Montaño; Hirotaka Oikawa; Angela C Sosa; Anping Chen; William S Sly
Journal:  Mol Genet Metab       Date:  2012-07-14       Impact factor: 4.797

8.  Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities.

Authors:  Susan Wilson; Saadat Hashamiyan; Lorne Clarke; Paul Saftig; John Mort; Valeria M Dejica; Dieter Brömme
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

Review 9.  Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.

Authors:  Sun H Peck; Margret L Casal; Neil R Malhotra; Can Ficicioglu; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2016-06-04       Impact factor: 4.797

Review 10.  Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA.

Authors:  Hira Peracha; Kazuki Sawamoto; Lauren Averill; Heidi Kecskemethy; Mary Theroux; Mihir Thacker; Kyoko Nagao; Christian Pizarro; William Mackenzie; Hironori Kobayashi; Seiji Yamaguchi; Yasuyuki Suzuki; Kenji Orii; Tadao Orii; Toshiyuki Fukao; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2018-05-15       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.